Osteocel® Plus in eXtreme Lateral Interbody Fusion (XLIF®)

NuVasive104 enrolled

Overview

This is a prospective, non-randomized multi-center study to compare the use of Osteocel® Plus in subjects who receive XLIF® (eXtreme Lateral Interbody Fusion) surgery at one or two levels. These subjects will present with degenerative conditions in the lumbar spine that are amenable to surgical treatment and will be screened prior to study enrollment. Subjects will receive Osteocel Plus during their XLIF operation. Subjects will be followed for 24-months following surgery to determine the number of study subjects that are solidly fused at or before 24 months postoperatively, and to determine the mean time to fusion. This data will be compared to published and/or retrospective data for autograft, synthetic ceramics and Bone Morphogenetic Protein (BMP).

Osteocel Plus is an allograft cellular bone matrix containing native mesenchymal stem cells (MSCs) which is intended to mimic the biologic performance of autograft without the morbidity associated with the autograft harvest. Mesenchymal stem cells, like those found in Osteocel Plus, are naturally occurring in the body and can differentiate into a variety of tissue types, depending on the local environment. Once implanted, MSCs can differentiate into osteoblasts, which produce new bone matrix. MSCs also naturally secrete bone-inducing growth factors that signal the patient's endogenous cells to migrate and participate in the bone formation process. Osteocel Plus is different from other orthobiologic products such as DBM and allograft cancellous bone because it contains living stem cells, which provide osteogenic potential. The cells include mesenchymal stem cells from an adult human donor; they are not from an embryonic source. This study is being conducted to determine the percentage of patients with solid spinal fusions after being treated with Osteocel in an XLIF procedure. Due to the unique processing conditions, Osteocel Plus retains a high concentration of stem cells in conjunction with the allograft bone matrix, so it is hypothesized that the fusion rate with Osteocel Plus will be comparable to published data for autograft. The Osteocel product family has already been used in approximately 15,000 cases worldwide.

Study Type

OBSERVATIONAL

Enrollment

104

Conditions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Persistent back and/or leg pain unresponsive to conservative treatment for at least six (6) months, unless clinically indicated earlier 2. Indicated for interbody fusion of one or two contiguous lumbar segments (L1 to L5) 3. Objective evidence of primary diagnosis must be confirmed by appropriate imaging studies 4. 18-80 years of age at the date of written informed consent 5. Able to undergo surgery based on physical exam, medical history and surgeon judgment 6. Expected to survive at least 2 years beyond surgery 7. Willing and able to return for post-treatment exams according to the follow-up called for in the protocol 8. Signed and dated Informed Consent Form Exclusion Criteria: 1. Patient has a mental or physical condition that would limit the ability to comply with study requirements 2. Lumbar spine abnormality requiring treatment at more than two levels 3. Systemic or local infection; active or latent 4. Previous failed fusion at the operative level 5. Diseases that significantly inhibit bone healing (osteoporosis, metabolic bone disease, uncontrolled diabetes, dialysis dependent renal failure, symptomatic liver disease) 6. Undergoing chemotherapy or radiation treatment, or chronic use of steroids (defined as more than 6 weeks of steroid use within 12 months of surgery, other than episodic use or inhaled corticosteroids) 7. Pregnant, or plans to become pregnant during the study 8. Subject is a prisoner 9. Involvement in active litigation relating to the spine (worker's compensation claim is allowed if it is not contended) 10. A significant general illness (e.g., HIV, active metastatic cancer of any type) is present; subject is immunocompromised or is being treated with immunosuppressive agents 11. Participating in another clinical study that would confound study data

Locations (13)

Shiley Center for Orthopaedic, Scripps Green Hospital

La Jolla, California, United States

Broward Spine Institute

Hollywood, Florida, United States

South Florida Spine Institute, Mount Sinai Medical Center

Miami Beach, Florida, United States

Southeastern Spine Center, Doctors Hospital of Sarasota

Sarasota, Florida, United States

USF, Tampa General Hospital

Tampa, Florida, United States

Pinnacle Orthopaedics, Wellstone Kennestone Hospital

Marietta, Georgia, United States

The Spine Center of DuPage Medical Group, Edward Hospital

Naperville, Illinois, United States

Indiana Center for Neurosurgery

Indianapolis, Indiana, United States

Columbia Orthopaedic Group, Boone Hospital Center

Columbia, Missouri, United States

Spine Midwest, St. Mary's Health Center

Jefferson City, Missouri, United States

...and 3 more locations

Outcomes

Primary Outcomes

The proportion of subjects with radiographically apparent fusion.

Time frame: 6-months, 12-months and 24-months

Secondary Outcomes

The evaluation of angular displacement on flexion/extension films.

Time frame: Post-op, 6-week, 3-month, 6-month, 12-month, 24-month

The evaluation of bridging bone on CT.

Time frame: 6-month, 12-month

Preservation of interbody height over time.

Time frame: All post-operative follow-up visits: Post-op, 6-week, 3-month, 6-month, 12-month, 24-month

The rate of complications attributable to the use of Osteocel Plus requiring intervention.

Time frame: All study follow-up visits: Post-op, 6-week, 3-month, 6-month, 12-month, 24-month

The change in subject self-reported pain ratings (VAS scores).

Time frame: from baseline through post-operation follow-up (visits at post-op, 6-week, 3-month, 6-month, 12-month and 24-months)

The change in Oswestry Disability Index scores.